Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of RP902 Tablets in the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease

NCT07579884 is registered in ClinicalTrials.gov with Risen (Suzhou) Pharma Tech Co., Ltd. as lead sponsor.

NCT NCT07579884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07579884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of RP902 Tablets in the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease
Lead sponsor
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
July 14, 2026
Completion date
May 31, 2031
Enrollment
360 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive impairment (mci)